MARKET

ABCL

ABCL

Abcellera Biologics Inc.
NASDAQ
5.24
-0.03
-0.57%
Pre Market: 5.49 +0.25 +4.77% 04:49 06/15 EDT
OPEN
5.30
PREV CLOSE
5.27
HIGH
5.41
LOW
5.13
VOLUME
3.98K
TURNOVER
0
52 WEEK HIGH
6.79
52 WEEK LOW
2.450
MARKET CAP
1.60B
P/E (TTM)
-10.9258
1D
5D
1M
3M
1Y
5Y
1D
AbCellera Biologics (ABCL) Stock Valuation After Adding Drug Development Expert Victor Sandor To The Board
Simply Wall St · 1h ago
Is AbCellera (ABCL) Using Boardroom Oncology Talent to Redefine Its Clinical Ambitions?
Simply Wall St · 2d ago
AbCellera Shareholders Back Directors, Auditors, Executive Pay
TipRanks · 2d ago
AbCellera shareholders elect John Montalbano, Stephen Quake as Class III directors
PUBT · 2d ago
Largest borrow rate increases among liquid names
TipRanks · 2d ago
AbCellera files Form 3 for director Victor Sandor, reporting no beneficial ownership
PUBT · 3d ago
AbCellera: Q3 Hot Flashes Data Drop Aside, This Stock Is A Difficult Sell
Seeking Alpha · 5d ago
Weekly Report: what happened at ABCL last week (0601-0605)?
Weekly Report · 6d ago
More
About ABCL
AbCellera Biologics Inc. discovers and develops antibody medicines for indications across therapeutic areas, including cancer, metabolic and endocrine conditions, and autoimmune disorders. Its platform integrates technology, data science, infrastructure, and interdisciplinary teams to solve the challenging antibody discovery problems. It is focused on advancing an internal pipeline of programs and collaborating on drug development programs with partners. Its first two internal programs, ABCL635 and ABCL575, are in late-preclinical studies. ABCL635 is an antibody drug candidate for metabolic and endocrine conditions, and ABCL575 is an antibody drug candidate with broad potential in inflammatory conditions and autoimmune diseases and an initial indication in atopic dermatitis. ABCL575 binds OX40L to disrupt OX40/OX40L signaling, a regulator of inflammatory pathways in AD. In addition to ABCL635 and ABCL575, it is advancing a pipeline of more than 20 internal discovery programs.

Webull offers AbCellera Biologics Inc stock information, including NASDAQ: ABCL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ABCL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ABCL stock methods without spending real money on the virtual paper trading platform.